Clinical Trials Logo

Tobacco clinical trials

View clinical trials related to Tobacco.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02576899 Completed - Clinical trials for Posttraumatic Stress Disorder

Improving Functional Outcomes of Veterans With PTSD and Tobacco Dependence

ACT-PT
Start date: September 1, 2015
Phase: Phase 1
Study type: Interventional

Veterans with PTSD have high rates of smoking (34%-86% vs. 18% in the general population) and have substantial difficulties with quitting tobacco. Despite the significant morbidity and mortality associated with smoking, no smoking cessation treatments exist that intensively target PTSD symptoms as an obstacle to quit smoking, although this is a significant barrier to quitting for many Veterans. In addition, no smoking cessation treatments have a large emphasis on improving the functioning of Veterans with PTSD and tobacco dependence, although both PTSD and tobacco use negatively affect functioning across physical, mental health, and social domains. The goal of this SPiRE project is to evaluate Acceptance and Commitment Therapy for Veterans with PTSD and Tobacco Use (ACT-PT), which is an acceptance and mindfulness-based smoking cessation treatment for Veterans with PTSD and tobacco dependence. ACT-PT specifically targets smoking cravings related to PTSD symptoms and memories of trauma, in addition to difficulties managing PTSD symptoms. negative affect and nicotine withdrawal symptoms during quit attempts. ACT-PT includes structured intervention components that guide Veterans to replace smoking as a coping strategy for PTSD symptoms and memories with alternative coping strategies (e.g., mindfulness, acceptance). And healthy living activities (e.g., engaging in work, expanding social networks, engaging in physical exercise) that are consistent with Veterans' values. This project involves a small randomized clinical trial study of Veteran smokers with PTSD and tobacco dependence randomized to one of two different types of psychosocial treatment: ACT-PT versus the American Lung Association's Freedom From Smoking Program [FFS]. This study has two primary aims: 1) evaluate the relative feasibility and acceptability of the two interventions (including ease of recruitment, randomization proportion, staff and Veteran acceptance of the treatment, retention rates, treatment adherence, fidelity, ease of the assessment process), and 2) evaluate the preliminary efficacy of ACT-PT vs. FFS with the primary outcomes of tobacco use, PTSD symptoms, health-related quality of life, and functional impairment.

NCT ID: NCT01938976 Completed - Asthma Clinical Trials

Efficacy of School-Based, Peer-Led Asthma and Smoking Prevention Program on CO1 Levels and Smoking Behavior Among Early Adolescents in Jordan

TAJPlus
Start date: October 2012
Phase: Phase 2
Study type: Interventional

Study Hypotheses: 1. adolescents in intervention schools who are given Triple A program plus ASP will show more awareness in regards to cigarettee smoking health effects and less nicotine dependencethan those in the control schools who are given Triple A alone. 2. adolescents with asthma in intervention schools who are given Triple A program plus ASP will show less asthma symptoms and better control than those in the control schools who are given Triple A alone. 3. adolescent smokers and passive smokers will exhibit higher levels of carbon monoxide (CO) in their breath than those who are not active or passive smokers. 4. there is a positive correlation between self-report questions regarding student smoking status and levels of CO in their breath

NCT ID: NCT01282008 Completed - Smoking Clinical Trials

Message Testing for Tobacco-Related Corrective Statements

Start date: January 21, 2011
Phase:
Study type: Observational

BACKGROUND: This document outlines the study design and procedures to be used to evaluate a series of corrective statements to augment consumer knowledge and beliefs about smoking as related to past actions of tobacco companies. The statements were ordered by a U.S. Federal Court in U.S. v. Philip Morris USA, Inc., and are intended to target potential misperceptions resultant of past marketing and promotion practices undertaken by the tobacco industry. OBJECTIVES: The U.S. Department of Justice has asked NCI to take the lead on developing and testing corrective statements with adult and youth audiences to ensure both message comprehension and avoidance of unintended consequences of message exposure, such as boomerang effects, smoking triggers, or knowledge gaps. The court has identified five areas that the statements shall address: 1. The adverse health effects of smoking; 2. The addictiveness of smoking and nicotine; 3. The lack of any significant health benefit from smoking low tar, light, ultra light, mild, and natural cigarettes; 4. The tobacco industry s manipulation of cigarette design and composition to ensure optimum nicotine delivery; 5. The adverse health effects of secondhand smoke. ELIGIBILITY: Message testing will be undertaken with the following audiences: - Current smokers (with an oversample of low socioeconomic status individuals) - General population nonsmokers and former smokers (with an oversample of low socioeconomic status individuals) - Spanish-speaking Hispanics - Youth age 14-17 DESIGN: Both qualitative and quantitative methods (focus groups and post-test comparison group Web-enabled surveys) will be used to develop and test a range of corrective statements in the five areas outlined by the court. - Focus group participants: 48-64 - Survey participants: 2500